Primary Sclerosing Cholangitis Market to Register Incremental Growth During the Forecast Period (2022-2032), Asserts DelveInsight | Key Companies – HighTide Biopharma, Dr. Falk Pharma, Albireo, IPSEN

DelveInsight’s “Primary Sclerosing Cholangitis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Primary Sclerosing Cholangitis, historical and forecasted epidemiology as well as the Primary Sclerosing Cholangitis market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the Primary Sclerosing Cholangitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Primary Sclerosing Cholangitis Market Forecast

Some of the key facts of the Primary Sclerosing Cholangitis Market Report: 

• The Primary Sclerosing Cholangitis market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In 2022, there were approximately 53,081 diagnosed prevalent PSC cases in the 7MM, with roughly 30,429 of those cases occurring in the US. During the prediction period (2023-2032), it is anticipated that these cases will rise
• The number of diagnosed prevalent Primary Sclerosing Cholangitis cases in the US was estimated to reach 57% of all cases in the 7MM in 2022, and it is anticipated that this number will rise during the course of the study period (2019–2032)
• There were roughly 20,692 men and 9,737 females among the most common instances of Primary Sclerosing Cholangitis in 2022, and this number is expected to rise over the course of the projection period
• Around 35,515 diagnosed PSC cases with IBD were found in the 7MM. The number of diagnosed PSC patients with IBD in EU4 and the UK was 12,471 in 2022, and it is anticipated that this number would rise over the study period
• Key Primary Sclerosing Cholangitis Companies: HighTide Biopharma, Dr. Falk Pharma, Albireo, IPSEN, Pliant Therapeutics, Inc., Chemomab Therapeutics, Mirum Pharmaceuticals, Albireo, Tobira Therapeutics, Inc., Ipsen, Mirum Pharmaceuticals, Inc., Pliant Therapeutics, Inc., Gilead Sciences, Intercept Pharmaceuticals, Mirum Pharmaceuticals, Inc., CymaBay Therapeutics, Inc., HighTide Biopharma Pty Ltd, Mayo Clinic, and others
• Key Primary Sclerosing Cholangitis Therapies: HTD1801, Norursodeoxycholic acid, A3907, PLN-74809, CM-101, Volixibat, A3907, Cenicriviroc, Elafibranor, Volixibat, PLN-74809 Cilofexor, norUDCA, Obeticholic Acid (OCA), LUM001, Seladelpar, HTD1801, Curcumin, and others
• The Primary Sclerosing Cholangitis epidemiology based on gender analyzed that in the US the diagnosed prevalence of Primary Sclerosing Cholangitis is higher in males than females
• The Primary Sclerosing Cholangitis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Primary Sclerosing Cholangitis pipeline products will significantly revolutionize the Primary Sclerosing Cholangitis market dynamics.

Primary Sclerosing Cholangitis Overview

Primary sclerosing cholangitis (PSC), according to the American Liver Foundation, is a chronic or long-term condition that slowly deteriorates the bile ducts. Due to inflammation, scarring, or fibrosis, the bile ducts get blocked in PSC patients, causing a buildup of bile in the liver that eventually kills liver cells and results in cirrhosis or liver fibrosis.

Get a Free sample for the Primary Sclerosing Cholangitis Market Report –

https://www.delveinsight.com/sample-request/primary-sclerosing-cholangitis-market

Primary Sclerosing Cholangitis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Primary Sclerosing Cholangitis Epidemiology Segmentation:

The Primary Sclerosing Cholangitis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Primary Sclerosing Cholangitis
• Prevalent Cases of Primary Sclerosing Cholangitis by severity
• Gender-specific Prevalence of Primary Sclerosing Cholangitis
• Diagnosed Cases of Episodic and Chronic Primary Sclerosing Cholangitis

Download the report to understand which factors are driving Primary Sclerosing Cholangitis epidemiology trends @ Primary Sclerosing Cholangitis Epidemiology Forecast

Primary Sclerosing Cholangitis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Primary Sclerosing Cholangitis market or expected to get launched during the study period. The analysis covers Primary Sclerosing Cholangitis market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Primary Sclerosing Cholangitis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Primary Sclerosing Cholangitis Therapies and Key Companies

• HTD1801: HighTide Biopharma
• Norursodeoxycholic acid: Dr. Falk Pharma
• A3907: Albireo/IPSEN
• PLN-74809: Pliant Therapeutics, Inc.
• CM-101: Chemomab Therapeutics
• Volixibat: Mirum Pharmaceuticals

Discover more about therapies set to grab major Primary Sclerosing Cholangitis market share @ Primary Sclerosing Cholangitis Treatment Market

Primary Sclerosing Cholangitis Market Strengths

• The emerging treatment pipeline is robust with promising candidates in the late and mid-stage clinical trial with some having proven efficacy in phase II trials

Primary Sclerosing Cholangitis Market Opportunities

• Combination therapies covering several aspects of Primary Sclerosing Cholangitis pathogenesis are desirable to achieve clinical efficacy

Scope of the Primary Sclerosing Cholangitis Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Primary Sclerosing Cholangitis Companies: HighTide Biopharma, Dr. Falk Pharma, Albireo, IPSEN, Pliant Therapeutics, Inc., Chemomab Therapeutics, Mirum Pharmaceuticals, Albireo, Tobira Therapeutics, Inc., Ipsen, Mirum Pharmaceuticals, Inc., Pliant Therapeutics, Inc., Gilead Sciences, Intercept Pharmaceuticals, Mirum Pharmaceuticals, Inc., CymaBay Therapeutics, Inc., HighTide Biopharma Pty Ltd, Mayo Clinic, and others
• Key Primary Sclerosing Cholangitis Therapies: HTD1801, Norursodeoxycholic acid, A3907, PLN-74809, CM-101, Volixibat, A3907, Cenicriviroc, Elafibranor, Volixibat, PLN-74809 Cilofexor, norUDCA, Obeticholic Acid (OCA), LUM001, Seladelpar, HTD1801, Curcumin, and others
• Primary Sclerosing Cholangitis Therapeutic Assessment: Primary Sclerosing Cholangitis current marketed and Primary Sclerosing Cholangitis emerging therapies
• Primary Sclerosing Cholangitis Market Dynamics: Primary Sclerosing Cholangitis market drivers and Primary Sclerosing Cholangitis market barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Primary Sclerosing Cholangitis Unmet Needs, KOL’s views, Analyst’s views, Primary Sclerosing Cholangitis Market Access and Reimbursement 

To know more about Primary Sclerosing Cholangitis companies working in the treatment market, visit @ Primary Sclerosing Cholangitis Clinical Trials and Therapeutic Assessment

Table of Contents 

1. Primary Sclerosing Cholangitis Market Report Introduction

2. Executive Summary for Primary Sclerosing Cholangitis

3. SWOT analysis of Primary Sclerosing Cholangitis

4. Primary Sclerosing Cholangitis Patient Share (%) Overview at a Glance

5. Primary Sclerosing Cholangitis Market Overview at a Glance

6. Primary Sclerosing Cholangitis Disease Background and Overview

7. Primary Sclerosing Cholangitis Epidemiology and Patient Population

8. Country-Specific Patient Population of Primary Sclerosing Cholangitis 

9. Primary Sclerosing Cholangitis Current Treatment and Medical Practices

10. Primary Sclerosing Cholangitis Unmet Needs

11. Primary Sclerosing Cholangitis Emerging Therapies

12. Primary Sclerosing Cholangitis Market Outlook

13. Country-Wise Primary Sclerosing Cholangitis Market Analysis (2019–2032)

14. Primary Sclerosing Cholangitis Market Access and Reimbursement of Therapies

15. Primary Sclerosing Cholangitis Market Drivers

16. Primary Sclerosing Cholangitis Market Barriers

17.  Primary Sclerosing Cholangitis Appendix

18. Primary Sclerosing Cholangitis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services